These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9929505)

  • 1. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
    Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
    Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
    Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T
    Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
    Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans.
    Lavrijsen K; Van Houdt J; Van Dyck D; Hendrickx J; Lauwers W; Hurkmans R; Bockx M; Janssen C; Meuldermans W; Heykants J
    Drug Metab Dispos; 1990; 18(5):704-10. PubMed ID: 1981724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
    Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
    Vyas KP; Kari PH; Prakash SR; Duggan DE
    Drug Metab Dispos; 1990; 18(2):218-22. PubMed ID: 1971576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
    Remmel RP; Crews BC; Kozak KR; Kalgutkar AS; Marnett LJ
    Drug Metab Dispos; 2004 Jan; 32(1):113-22. PubMed ID: 14709628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
    Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
    Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
    Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
    Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
    Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of the anti-angiogenic compound SU5416.
    Antonian L; Zhang H; Yang C; Wagner G; Shawver LK; Shet M; Ogilvie B; Madan A; Parkinson A
    Drug Metab Dispos; 2000 Dec; 28(12):1505-12. PubMed ID: 11095590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
    Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
    Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
    Khier S; Gattacceca F; El Messaoudi S; Lafaille F; Deleuze-Masquéfa C; Bompart J; Cooper JF; Solassol I; Pinguet F; Bonnet PA; Bressolle FM
    Drug Metab Dispos; 2010 Oct; 38(10):1836-47. PubMed ID: 20660102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.